Additional factors have also been associated with response to PD-1 axis blockade including increased CD8+ tumor infiltrating lymphocytes (TILs)11,12, TIL PD-1 expression11, clonally expanded T-cell populations11 and elevated somatic mutations or candidate MHC class-I neoantigens12–14. The gene discussed is CD8A; the disease is neoplasm.